Ginkgo Bioworks Holdings, Inc. Class Action Lawsuit - DNA

(1) the Company’s failure to derive real revenue from third-party customers left it almost completely dependent on related parties; (2) as a result, most, if not all, of the Company’s revenue came from related parties the Company created, funded, or controlled through its ownership and board seats; (3) the Company was misclassifying and underreporting related party revenue in order to conceal the Company’s near total-dependence on related parties; (4) many of the Company’s new R&D partners are undisclosed related parties and/or façades; (5) as a result, the Company’s valuation was significant less than Defendants disclosed to investors; and (6) as a result, Defendants’ public statements were materially false and/or misleading at all relevant times.

In order to be eligible to join the DNA class action lawsuit, you must have incurred a loss on shares of Ginkgo Bioworks purchased during the class period listed above.

If you suffered a loss in Ginkgo Bioworks during the relevant time frame or pursuant to the relevant offering(s), you have until January 18, 2022 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.